Objective: To determine the magnitude and determinants of weight loss in humans exposed to betahistine, a centrally acting histamine-1 (H-1) agonist and partial histamine-3 (H-3) antagonist. Design: A multicenter randomized, placebo-controlled dose-ranging weight loss trial with a 12-week treatment period. Subjects: Two hundred and eighty-one obese but otherwise healthy participants. Measurements: Weight and obesity-related comorbidities at baseline and at the end of the intervention. Results: Betahistine, at the doses tested, did not induce significant weight loss. With the exception of headache, no difference in adverse effect profile was noted between placebo and treatment groups. Subgroup analysis revealed that age below 50 years, ethnicity (non-Hispanics) and gender (women) were the strongest predictors of weight loss in this population. When these three factors were combined together, the betahistine 48 mg group (n ¼ 23) lost À4.24 ± 3.87 kg, whereas the placebo group (n ¼ 25) lost À1.65±2.96 kg during this time period (P ¼ 0.005). Conclusion: Betahistine, at the doses tested, induced significant weight loss with minimal adverse events only in women below 50 years.
Introduction
Brain histamine has several functions including modulation of the neuroendocrine system, 1 drinking behavior, 2 sleep-wake cycles, 3 and feeding behavior. 4 The histamine receptors (H1, H2, H3 and H4) that are known at present are all members of the G-protein-coupled receptor family and they transduce extracellular signals through the G-proteins, Gq, Gs, Gi/o and Gi/o, respectively. For a full description of the histaminergic system and classification the reader is referred to an excellent review on the subject published recently. 5 The H1 and H3 receptors are important for regulating feeding. 6, 7 It is important to note that the H3 receptor is an autoreceptor that exists on presynaptic histaminergic fibers and regulates histamine synthesis and release in the central nervous system. 8 In other words, activation of the H3 receptor decreases histamine release to the synaptic cleft, whereas antagonizing its activity increases the secretion of histamine to the synaptic cleft. Thus, histamine binds to postsynaptic histamine receptors (H1 in the case of feeding behavior). Therefore, H3 antagonistic activity may be reclassified as inverse agonists. In 1973, Clineschmidt and Lotti 9 were the first to show that administration of histamine reduces food intake. They administered histamine into the lateral ventricle of cats and observed a long-term suppression of food intake. Itowi et al. 10 administered histamine continuously into the suprachiasmatic nucleus of the hypothalamus in rats. Similarly, they found that histamine reduced food intake. L-Histidine is an amino acid that is converted in the brain to histamine by histidine decarboxylase. Intraperitoneal injection of L-histidine, had the same effect as histamine in reducing food intake. [11] [12] [13] Administration of metoprine, an enzyme that blocks histamine breakdown, suppresses food intake in rats. 14,15 a-Fluoromethylhistidine is a specific and irreversible inhibitor of the histidine decarboxylase enzyme and has the ability to deplete histamine from the brain neurons. Intracerebroventricular administration of this compound significantly increases food intake in rats. [16] [17] [18] [19] Together, these findings provide consistent evidence for histamine being an anorexigenic agent. Betahistine, is an orally active, central nervous system penetrating, histamine-like drug used in the symptomatic treatment of vestibular disorders. 20 Betahistine's affinity for H1-receptor sites was comparable to that of histamine. 21 Apart from being a histamine-1 (H1) receptor agonist, betahistine has been shown to be a histamine (H3) receptor antagonist.
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Betahistine has a remarkable safety profile; a recent postmarketing assessment based on an estimated exposure of more than 130 million patients revealed a rate of reported adverse drug reactions to be 1:100 000. 23 We report here the results of a multicenter, multiple dose, phase 2 study that investigated the potential of betahistine to serve as an antiobesity agent.
Methods
This was a 15-week, multicenter, randomized, double-blind, placebo-controlled, dose-finding study with a 1-week screening period; a 2-week, single-blind placebo run-in period and a 12-week, double-blind treatment period (Figure 1 ).
The population for this study included obese (body mass index 430 to o40 kg/m 2 ) men and women between 18 and 65 years of age. All participants were obese for at least 1 year before the screening period. Exclusion criteria included obesity of endocrine or genetic origin, earlier surgical procedures for weight loss; body weight loss of 44 kg in the 90 days before screening; participants had taken drugs capable of influencing body weight 30 days before screening; participants had started or planned on starting a smoking cessation program; non-compliant with study medication in the single-blind placebo run-in period. Participation was also excluded if there was a clinically significant history or presence of any of the following conditions: cardiovascular or cerebrovascular disease; liver disease; type 1 diabetes mellitus; type 2 diabetes mellitus on treatment other than metformin monotherapy and/or diet with HbA1c o8%; renal insufficiency; malignant disease within 5 years of screening; thyroid hormone abnormality; uncontrolled hypertension; history of asthma; peptic ulcers or human immunodeficiency virus; psychiatric or neurological disorders requiring chronic medications; eating disorder; chronic or as-needed use of antihistamines.
A screening visit was used to determine suitability for inclusion in the trial. One week after the screening visit, eligible participants entered a 2-week single-blind placebo run-in period. During this period, participants received matching placebo and were stabilized onto a mildly hypocaloric diet, designed to provide their estimated total daily energy expenditure minus 600 kcal day
À1
. The total daily energy requirement was calculated by using the dietary recommended intake equations. 24 After the 2-week, singleblind placebo run-in period, participants found to be eligible for the study were randomly assigned to one of four treatment groups: betahistine 16, 32 or 48 mg day À1 or matching placebo. The primary objective of the study was to examine the effect of betahistine on body weight in obese participants. The secondary objectives were to investigate the effect of betahistine in obese participants on the following: waist circumference; other obesity-related risk factors (blood pressure, plasma lipids, hemoglobin A1c (HbA1c) and fasting plasma glucose); appetite and satiety score as determined by seven 100-mm visual analog scales; food intake as determined by self reporting of 3-day dietary logs and safety and tolerability of betahistine in obese participants.
Determination of sample size
A sample size of 63 completed participants per treatment group was calculated by assuming a difference of 3.5 kg and a standard deviation of 7 kg in change in body weight from baseline to end point between two treatment groups with 80% power at a two-sided significance level of 0.05. Participants were assigned randomly to one of four treatment groups in a 1:1:1:1 ratio. Double-blind study medication was packaged in numbered kits based on a randomization scheme provided by the clinical research organization. This scheme used blocks to ensure equal distribution of groups in each site.
Statistics
The intent-to-treat population included all randomized participants who received at least one dose of randomized study medication, had a baseline weight measurement Screening Figure 1 Study design.
Weight loss to betahistine N Barak et al and at least one post-baseline weight measurement. The per protocol population included all participants who completed the 12-week, double-blind treatment period in compliance with the protocol. The safety population included all participants who received at least one dose of randomized study medication. All statistical analyses were performed using the week 12 end point. All tests applied were two-tailed and a P-value of 5% or less was considered statistically significant. The data were analyzed using the SAS software (SAS Institute, Cary, NC, USA).
Descriptive statistics. Measured variables and derived parameters of the study are presented as appropriate. Categorical variables are presented by giving sample size and frequency. Continuous variables are presented by giving sample size, arithmetic mean, standard deviation and 95% confidence interval for means.
Univariate analysis. To examine the statistical significance of weight decrease within each group, the paired t-test or non-parametric sign rank test was applied. The appropriate test was selected according to the parameter's actual distribution.
T-test was applied for testing the differences in weight decrease between the treatment groups.
Statement of ethics
The authors certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. The protocol and informed consent document were submitted to and approved by the duly constituted Institutional Review Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure. Baseline was defined as the visit 3 (week 0) measurement. If the visit 3 measurement was missing, then the last measurement before the first dose of randomized study medication was used.
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Board for each site before initiation of the study. The ClinicalTrials.gov identifier for this study was NCT00409305.
Results Table 1 lists demographic and baseline characteristics data for all randomized participants. The initiation date for the study was 2 January 2007 and the completion date was 22 June 2007. Figure 2 shows the flow of participants through the study stages.
Efficacy results
For the intent-to-treat population (n ¼ 281), compared with placebo treatment, betahistine treatment at doses of 16, 32 and 48 mg day À1 did not result in statistically significant changes in weight. The least-squares mean change in weight from baseline to week 12 end point compared with placebo was 0.16 kg (adjusted P ¼ 0.986) for the betahistine 16 mg group, À0.12 kg (adjusted P ¼ 0.9906) for the betahistine 32 mg group and À0.12 kg (adjusted P ¼ 0.9907) for the betahistine 48 mg group (Figure 3) . Compared with placebo treatment, there were no statistically significant changes in waist circumference, hip circumference, ratio of waist circumference to hip circumference, body mass index, sitting systolic blood pressure, sitting diastolic blood pressure, fasting plasma glucose, lipids, and appetite and satiety scores. However, a statistically significant mean change in HbA1c was observed in the betahistine 48 mg group (0.04%, adjusted P ¼ 0.0295). This change, though statistically significant, was not considered clinically meaningful and no dose-related trend was observed.
Post hoc exploratory subgroup analyses
The objective of the subgroup analysis was to provide general information of study medication performance for a defined segment of the study population. These analyses investigated the treatment effect between betahistine 48 mg and placebo by using a multiple stepwise linear regression. The subgroups Weight loss to betahistine N Barak et al that were explored from the per protocol population were gender, ethnicity, age, weight loss during run-in period and race. The post hoc exploratory subgroup analysis revealed that the factors affecting weight response in the 48 mg group were age, ethnicity, gender and weight loss during the run-in period (Table 2) . For age, a scatter plot showed that the cut off for having a good response to the drug was 50 years of age. For gender, women responded better to the drug than men, for weight loss during the run-in period, a scatter plot showed that the cutoff was 1.5 kg. For ethnicity, nonHispanics responded better than Hispanics. Race had no effect on the response to the drug. Looking at the per protocol population of less than 50 years old, non-Hispanic women (n ¼ 23 for the betahistine 48 mg day À1 group and n ¼ 25 for the placebo group) showed a statistically and clinically significant weight loss (Figure 4 ). Based on 3-day dietary logs, the change in caloric intake for the betahistine 48 mg group was 192±1123 kcal day À1 (n ¼ 14) and placebo group was 77 ± 419 kcal day À1 (n ¼ 19).
Safety results
No deaths occurred during the study. The incidence of drugrelated treatment-emergent adverse events was similar across the treatment groups. The incidence of headache appeared to increase with an increase in betahistine dose (4.2% for the placebo group, 4.3% for the betahistine 16 mg group, 8.8% for the betahistine 32 mg group and 12.9% for the betahistine 48 mg group). Of the 21 participants who experienced headaches during the study, 7 participants experienced headache that was considered by the investigator to be related to study medication (three in the betahistine 48 mg group, three in the betahistine 32 mg group and one in the placebo group). Most incidence of headache was mild to moderate in severity (16 were mild, 4 were moderate and Weight loss to betahistine N Barak et al 1 was severe). One participant in the betahistine 32 mg group withdrew from the study due to the adverse event of headache. This event was considered related to study medication. The incidence of cutaneous hypersensitivity (including rash, pruritus and urticaria) was similar across the treatment groups, ranging from 5.9% in the betahistine 32 mg day À1 group to 1.4% in the betahistine 48 mg day À1 group.
Discussion
Overall, betahistine did not produce a statistically significant weight loss in the population studied; thus, it failed to meet the primary and secondary outcomes set for this study. Based on the adverse effect profile observed in this study, it would be reasonable to study a higher range of doses. Doses of betahistine as high as 48 mg day À1 are currently used in clinical practice for the treatment of Meniere's disease.
To better understand the effect of the drug on weight; a post hoc subgroup analysis was performed. This analysis was limited to a comparison between the placebo and the betahistine 48 mg groups. This subgroup analysis revealed that age, gender and ethnicity were the strongest predictors for weight loss in our study population. With respect to ethnicity issues, it is important to note that the group of Hispanics included in the betahistine 48 mg group consisted of only seven participants. Therefore, it would be premature to draw conclusions based on such a small group.
The fact that women younger than 50 years of age were the best responders to the drug warrants special attention. In animals, gender differences were observed in the central nervous system histamine receptor response to dietary manipulations. 25, 26 The histaminergic nerve cell bodies in the central nervous system are exclusively located in the tuberomammillary nucleus of the posterior hypothalamus. 27 These cells project their axons mainly to two areas: the paraventricular nucleus and ventromedial hypothalamus (VMH). 28 The paraventricular nucleus regulates feeding behavior influenced by the body's energy stores. Leptin directly interacts with thyrotropin-releasing hormone neurons in the paraventricular nucleus. 29 This interaction is mediated through histamine. 30 The VMH is typically involved in sexual arousal and mating behavior. 31 Patch-clamp recordings that measured the effect of histamine on the membrane potential of VMH neurons 32 revealed that estrogen treatment increased membrane potential in ovariectomized female mice. Hence, neurons in the VMH are responsible for the integration of nutritional signals with estrogenic signaling. This proposal makes sense in that it would not be biologically adaptive for women to reproduce at times when they do not have an adequate food supply. 30 Therefore, it seems that histamine has a role in two different systems that involve feeding behavior; one that relates to energy homeostasis and the other that relates to reproductive function ( Figure 5 ).
The interaction between estrogens, histamine and VMH neurons, serves to explain the results of our study in which a weight effect was observed only in women younger than 50 years, or in other words, in premenopausal women. To the best of our knowledge, this is the first report on possible estrogen-histamine interactions that effect feeding behavior in humans.
The major limitation of this report is that weight loss was observed only in a post hoc subgroup analysis. We would like to note that in the subpopulation of non-Hispanic women, younger than 50 years, no difference was observed in baseline characteristics between the placebo group and the betahistine 48 mg day À1 group.
Interpretation of positive results obtained from a subgroup analysis is a challenging task. When multiple interaction tests are conducted, each using a nominal criterion (that is, P ¼ 0.05) to assess statistical significance, the probability of a false positive result can be greatly inflated. To determine whether the results observed are truly significant, a correction factor (inflation factor) should be incorporated into the calculation. One way to correct this is to apply a stricter criterion than the usual P ¼ 0.05 for judging the significance of each interaction test. 33 If K-independent tests are
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Reproductive Behavior Energy Balance Figure 5 Schematic representation of the histaminergic neurons in the brain; histaminergic neurons are located in the tuberomammillary nucleus and project their axons to the ventromedial hypothalamus and to the paraventricular nucleus. In the paraventricular nucleus, these axons interact with leptin responsive neurons to affect energy homeostasis. In the ventromedial hypothalamus, these axons interact with estrogen sensitive neurons, thus linking reproduction with feeding behavior.
Weight loss to betahistine N Barak et al conducted, one way to ensure that the overall chances of a false-positive result are no greater than 5% (0.05) is for each test to use a criterion of 0.05/K, to assess statistical significance. 34 In our study, as k ¼ 5, statistical significance for P-value should be set at 0.01. As, in the group of nonHispanic women under 50 years of age, the weight difference observed between 48 mg treatment group and the placebo group, reached a P-value of 0.005, we believe that these results represent a true statistical significance. The large standard deviation (five times the mean) observed in the selfreported food intake, renders this assessment as inaccurate.
In conclusion, in this study betahistine failed to induce significant weight loss in obese participants, but the prevalence of adverse events was low, suggesting the need to test higher doses. There have been attempts to determine subgroups that might have enhanced efficacy to individual weight loss drugs. The greater weight loss effect of betahistine observed in women younger than 50 years warrants further investigation, may represent gender-associated properties of histamine and suggests a subgroup that may be most appropriate for treatment with betahistine.
